Class summary at a glance.

Every drug in the Interleukin-12 Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $5.16Bcombined across class
Total Rx claims: 200K48K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ustekinumab

Brand: STELARA · 199K Part D claims (CY24) · 48K beneficiaries · First FDA approval: 2009-09-25

Brand-only (no generics) 1644 plans require PA

Low NADAC$2898.19

→

Avg plan cost$20844.79

Part D spend $5.16B 7× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Ustekinumab-Auub

Brand: WEZLANA · 283 Part D claims (CY24) · 199 beneficiaries · First FDA approval: 2025-01-01

Brand-only (no generics) 78 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.8M

Class share

of class CY24 spend

View profile →

Ustekinumab-Aekn

Brand: SELARSDI · 65 Part D claims (CY24) · 44 beneficiaries · First FDA approval: 2025-03-12

Brand-only (no generics) 512 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $233857

Class share

of class CY24 spend

View profile →

Ustekinumab-Aauz

Brand: Otulfi · — Part D claims (CY24) · First FDA approval: 2024-02-22

Brand-only (no generics) 156 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ustekinumab-Hmny

Brand: Starjemza · — Part D claims (CY24) · First FDA approval: 2025-10-27

Brand-only (no generics) 102 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ustekinumab-Ttwe

Brand: PYZCHIVA · — Part D claims (CY24) · First FDA approval: 2025-02-22

Brand-only (no generics) 519 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.